Montelukast 10MG + Levocetirizine 5MG Tablets are a combination oral solid dosage formulation containing two active pharmaceutical ingredients in a single tablet. The development of such a formulation requires careful control over active-ingredient distribution, excipient compatibility, powder flow, compression parameters and finished-product stability. For pharmaceutical companies developing a diversified oral dosage portfolio, this combination can also be incorporated into a structured PCD Pharma Franchise product range.
The formulation contains Montelukast 10MG and Levocetirizine 5MG along with suitable pharmaceutical-grade excipients. Depending on the approved formulation design, the tablet may contain diluents, binders, disintegrants, lubricants, glidants and other functional excipients. Each component is selected and optimized according to its role in manufacturing and finished-product quality.
The first stage of developing Montelukast 10MG + Levocetirizine 5MG Tablets involves evaluating the compatibility of both active ingredients with the selected excipient system. Since two different active ingredients are present in the same dosage form, the formulation must provide consistent distribution of both components.
Diluents may be used to establish the required tablet weight and improve powder-handling characteristics. Binders can contribute to suitable tablet strength, while disintegrants support appropriate tablet breakup after compression. Lubricants and glidants may be incorporated in controlled quantities to improve powder flow and tablet ejection.
Pre formulation studies can assess particle characteristics, moisture sensitivity, flow properties and potential interactions between the active ingredients and excipients. These evaluations help determine a suitable formulation platform before commercial-scale manufacturing.
The final excipient ratio is optimized through development trials to achieve appropriate compressibility, physical integrity and stability without compromising the intended quality specifications.
Manufacturing starts with the accurate dispensing of Montelukast, Levocetirizine and all supporting excipients according to the approved batch manufacturing formula. Raw materials are verified against their respective specifications before being released for production.
Particle-size distribution and flow characteristics can influence the uniformity of the final powder blend. Therefore, suitable preprocessing such as sieving may be performed where required.
The active ingredients are incorporated into the formulation according to a controlled mixing sequence. Particular attention is given to achieving a homogeneous distribution of both active ingredients because the two components are present at different strengths.
Blending parameters such as mixing time, sequence of addition and equipment settings are established during process development. Representative samples may be tested for blend uniformity before compression.
Depending on the manufacturing approach, the blend may be processed through direct compression or an appropriate granulation method. In a granulation-based process, parameters such as granule size, moisture content and flow properties may be monitored before the compression stage.
The prepared blend is compressed using suitable tooling and controlled machine parameters. Compression force, machine speed and powder-feeding conditions can influence tablet weight, thickness, hardness and friability.
In-process checks are performed at defined intervals to monitor average weight and weight variation. These controls help maintain consistency across the entire compression batch.
Tablet hardness is evaluated to ensure adequate mechanical strength for subsequent handling, dedusting, packaging and transportation. However, excessive compression may affect the tablet's disintegration behavior, so compression parameters are optimized during formulation development.
Friability testing provides information about the tablet's resistance to mechanical abrasion. Visual inspection may also be performed to identify capping, lamination, chipping, sticking or other compression-related defects.
Disintegration testing can be included as part of the finished-product quality program to verify that the tablets meet their established specification. Consistent tablet dimensions and surface appearance also contribute to standardized product presentation.
Quality-control testing is carried out to confirm that Montelukast 10MG + Levocetirizine 5MG Tablets meet their predefined specifications. Identification and assay of both active ingredients can be performed using suitable validated analytical procedures.
Finished-product testing may include uniformity of dosage units, average weight, weight variation, hardness, thickness, friability, disintegration and dissolution, depending on the approved specification.
Since the formulation contains two active ingredients, analytical methods should provide reliable identification and quantification of each component within the finished dosage form. Related substances and degradation-related parameters may also be monitored where applicable.
Stability studies are performed under defined storage conditions to assess the product's behavior over time. Samples may be evaluated periodically for changes in appearance, assay, degradation profile, dissolution, disintegration and physical characteristics.
Stability data supports the establishment of suitable storage conditions and helps determine whether the selected formulation and packaging system can maintain product quality throughout the proposed shelf life.
Packaging development is an important final stage for Montelukast 10MG + Levocetirizine 5MG Tablets. The selected packaging system should provide suitable protection against moisture, contamination and physical damage during storage and transportation.
Blister packs, strip packs or other suitable packaging configurations may be selected according to the stability characteristics and approved packaging specifications. Packaging materials should be assessed for compatibility with the formulation, while seal integrity can be evaluated to maintain protection throughout the product's shelf life.
The final packaging artwork should include the required composition, batch details, manufacturing information, storage conditions and other applicable regulatory particulars. Consistent packaging specifications can help maintain a professional and recognizable product presentation.
For pharmaceutical manufacturers and marketers, this combination tablet can complement a broader oral solid-dose portfolio. Accurate raw-material dispensing, controlled blending, optimized compression, analytical testing and stability monitoring contribute to consistent product quality.
For companies developing a diversified PCD Pharma Franchise portfolio, standardized manufacturing procedures, documented specifications and professional packaging can support organized product management and consistent presentation across the pharmaceutical distribution network.
Montelukast 10MG + Levocetirizine 5MG Tablets with formulation, manufacturing, quality control, stability, packaging and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech